LEAD cohort Sample Clauses

LEAD cohort. The Xxxxxx-Xxxxx survival probabilities in 1 year, 3 years and 5 years in terms of three outcomes were summarized in Table 2 and the survival curves comparing two relapse detection groups were shown in Figure 1. Hazard ratios (HRs) and p-values given by all the Xxx PH models in LEAD cohort were summarized in supplementary Table S1. The estimated median PFS time in this cohort is 4.2 years (95% CI: 2.5-6) in clinical detection group and 3.6 years (95% CI: 1.8-4.4) in SI detection group. Although it seemed that SI led to an earlier detection of relapse based on median PFS time, there was no statistically significant difference in survival probabilities between two groups with a p-value of 0.2895 given by the two-sample log-rank test. The simple Xxx PH model gave the same result with a p-value of 0.291 in Wald test (HR of SI group=1.37, 95% CI: 0.76-2.45). After controlling for the confounders – ethnicity, ECOG, FLIPI, B- symptoms and age, no apparent difference in patient survival was detected from the multivariable model (HR of SI group=1.71, 95% CI: 0.77-3.80, p-value=0.187). In terms of the other two survival outcomes, survival probabilities and risk of death were also not significantly different between patients in two groups. For OS from diagnosis, the p-value was 0.5324 in log-rank test and 0.537 in simple Xxx model (HR of SI group=0.61, 95% CI: 0.13-2.94). In the multivariable Xxx model with covariates gender, stage, grade, ECOG, B-symptoms and age, the HR was 0.14 (95% CI: 0.01-3.36) with a p-value of 0.222. For OS from relapse, the p-value was 0.3346 in log- rank test and 0.346 in simple Xxx model (HR of SI group=0.47, 95% CI: 0.10-2.28). In the multivariable Xxx model with covariates grade and ECOG, the HR was 0.28 (95% CI: 0.03-2.51) with a p-value of 0.255. Results of the Supremum tests for checking proportional hazard assumption in the three multivariate Xxx models in LEAD cohort were summarized in Table S3. None of the variables included in the three models violated the PH assumption as all the test results were non- significant at the alpha level of 0.05.
Sample 1
AutoNDA by SimpleDocs

Related to LEAD cohort

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Project Management Plan 1 3.4.1 Developer is responsible for all quality assurance and quality control 2 activities necessary to manage the Work, including the Utility Adjustment Work.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act.

  • Professional Development Plan Professional Development Plan (PDP) refers to plans developed by faculty members addressing the criteria contained in Article 22 and Appendix G.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Professional Development Program (a) The parties agree to continue a Professional Development Program for the maintenance and development of the faculty members' professional competence and effectiveness. It is agreed that maintenance of currency of subject knowledge, the improvement of performance of faculty duties, and the maintenance and improvement of professional competence, including instructional skills, are the primary professional development activities of faculty members.

  • Statewide HUB Program Statewide Procurement Division Note: In order for State agencies and institutions of higher education (universities) to be credited for utilizing this business as a HUB, they must award payment under the Certificate/VID Number identified above. Agencies, universities and prime contractors are encouraged to verify the company’s HUB certification prior to issuing a notice of award by accessing the Internet (xxxxx://xxxxx.xxx.xxxxx.xx.xx/tpasscmblsearch/index.jsp) or by contacting the HUB Program at 000-000-0000 or toll-free in Texas at 0-000-000-0000.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

Time is Money Join Law Insider Premium to draft better contracts faster.